Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex’s GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.
Metrics to compare | 4503 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4503PeersSector | |
---|---|---|---|---|
P/E Ratio | −44.7x | 22.7x | −0.6x | |
PEG Ratio | 0.03 | −0.38 | 0.00 | |
Price/Book | 1.7x | 3.2x | 2.6x | |
Price / LTM Sales | 1.4x | 3.3x | 3.1x | |
Upside (Analyst Target) | 39.5% | 15.7% | 48.2% | |
Fair Value Upside | Unlock | 21.2% | 8.0% | Unlock |